In 2018 Nanolek will fully cover the needs of Russian market in IPV


Today, the world faces problems in meeting the demand for inactivated polio vaccine (IPV), which can be explained by increased global needs in this medicine. These needs are associated with the phased global transition to the use of IPV by 2019 in accordance with the Global Polio Eradication Strategic Plan of the World Health Organization, announced the press service of the Russian Ministry of Health.

As a result of artificial shortage, the volumes of monovalent vaccine delivered to Russia fell by 13.6 times from 2.3 million to 169 thousand doses.

Therefore, the Russian Ministry of Health, together with the Ministry of Industry and Trade of Russia, urgently adopted all necessary organizational measures, including the steps to accelerate the import substitution of IPV in Russia by localizing the manufacturing at Nanolec production facilities and introduced changes to regulatory legal acts in order to allow the use of pentavalent vaccine with Polio component.

As early as 2018, Nanolek will reach the production volume of IPV that fully covers the needs in vaccine and ensures uninterrupted supplies to the regions. Moreover, M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitis has developed a Russian IPV, the clinical trials which will begin in the near future.

This situation with IPV once again demonstrates the need for active import substitution in such strategically important area as public vaccination.